Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label scandinavian noninterventional study (The scansmart study)

Elena Didenko Pedersen*, Egon Stenager, J. L. Vadgaard, M. B. Jensen, R. Schmid, N. Meland, G. Magnussen, Jette L. frederiksen

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

99 Downloads (Pure)

Resumé

Background: Disease modifying drugs help control the course of relapsing remitting multiple sclerosis (RRMS); however, good adherence is needed for long-term outcomes. Objective: To evaluate patient adherence to treatment with subcutaneous interferon beta-1a using RebiSmart® and assess injection-site reactions and treatment satisfaction. Methods: This prospective, single-arm, open-label, noninterventional multicenter Phase IV trial included disease modifying drug-experienced mobile patients with RRMS. Adherence was measured over 12 weeks. Items 13–23, 35, 37, and 38 of the Multiple Sclerosis Treatment Concerns Questionnaire (injection-site reactions and treatment satisfaction) were recorded at 12 weeks. Results: Sixty patients were recruited (mean age 43.7 [±SD 7.9] years; 83% female; mean years since multiple sclerosis diagnosis 6.7 [SD 4.5]). Adherence data were obtained in 54 patients only due to technical problems with six devices. Over 12 weeks, 89% (n=48) of patients had ≥ 90% adherence to treatment. Most patients experienced mild influenza-like symptoms and injection-site reactions, and global side effects were minimal. Most patients (78%) rated the convenience as the most important aspect of the device, and most experienced no or mild pain. Conclusion: RRMS patients treated with subcutaneous interferon beta-1a, administered with RebiSmart, demonstrated generally good adherence, and the treatment was generally well tolerated.

OriginalsprogEngelsk
TidsskriftPatient Preference and Adherence
Vol/bind12
Sider (fra-til)569-575
ISSN1177-889X
DOI
StatusUdgivet - 2018

Fingeraftryk

multiple sclerosis
electronics
Equipment and Supplies
Relapsing-Remitting Multiple Sclerosis
drug
Disease
contagious disease
pain
Drug and Narcotic Control
Human Influenza
questionnaire
Pharmaceutical Preparations

Citer dette

Pedersen, Elena Didenko ; Stenager, Egon ; Vadgaard, J. L. ; Jensen, M. B. ; Schmid, R. ; Meland, N. ; Magnussen, G. ; frederiksen, Jette L. / Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device : a prospective open-label scandinavian noninterventional study (The scansmart study). I: Patient Preference and Adherence. 2018 ; Bind 12. s. 569-575.
@article{4b4d49bc87d6410faf38c52c43143b45,
title = "Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label scandinavian noninterventional study (The scansmart study)",
abstract = "Background: Disease modifying drugs help control the course of relapsing remitting multiple sclerosis (RRMS); however, good adherence is needed for long-term outcomes. Objective: To evaluate patient adherence to treatment with subcutaneous interferon beta-1a using RebiSmart{\circledR} and assess injection-site reactions and treatment satisfaction. Methods: This prospective, single-arm, open-label, noninterventional multicenter Phase IV trial included disease modifying drug-experienced mobile patients with RRMS. Adherence was measured over 12 weeks. Items 13–23, 35, 37, and 38 of the Multiple Sclerosis Treatment Concerns Questionnaire (injection-site reactions and treatment satisfaction) were recorded at 12 weeks. Results: Sixty patients were recruited (mean age 43.7 [±SD 7.9] years; 83{\%} female; mean years since multiple sclerosis diagnosis 6.7 [SD 4.5]). Adherence data were obtained in 54 patients only due to technical problems with six devices. Over 12 weeks, 89{\%} (n=48) of patients had ≥ 90{\%} adherence to treatment. Most patients experienced mild influenza-like symptoms and injection-site reactions, and global side effects were minimal. Most patients (78{\%}) rated the convenience as the most important aspect of the device, and most experienced no or mild pain. Conclusion: RRMS patients treated with subcutaneous interferon beta-1a, administered with RebiSmart, demonstrated generally good adherence, and the treatment was generally well tolerated.",
keywords = "Adherence, Multiple sclerosis, RebiSmart, Relapsing remitting MS, Subcutaneous interferon beta-1a, Trial",
author = "Pedersen, {Elena Didenko} and Egon Stenager and Vadgaard, {J. L.} and Jensen, {M. B.} and R. Schmid and N. Meland and G. Magnussen and frederiksen, {Jette L.}",
year = "2018",
doi = "10.2147/PPA.S154417",
language = "English",
volume = "12",
pages = "569--575",
journal = "Patient Preference and Adherence",
issn = "1177-889X",
publisher = "Dove Medical Press Ltd.(Dovepress)",

}

Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device : a prospective open-label scandinavian noninterventional study (The scansmart study). / Pedersen, Elena Didenko; Stenager, Egon; Vadgaard, J. L.; Jensen, M. B.; Schmid, R.; Meland, N.; Magnussen, G.; frederiksen, Jette L.

I: Patient Preference and Adherence, Bind 12, 2018, s. 569-575.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device

T2 - a prospective open-label scandinavian noninterventional study (The scansmart study)

AU - Pedersen, Elena Didenko

AU - Stenager, Egon

AU - Vadgaard, J. L.

AU - Jensen, M. B.

AU - Schmid, R.

AU - Meland, N.

AU - Magnussen, G.

AU - frederiksen, Jette L.

PY - 2018

Y1 - 2018

N2 - Background: Disease modifying drugs help control the course of relapsing remitting multiple sclerosis (RRMS); however, good adherence is needed for long-term outcomes. Objective: To evaluate patient adherence to treatment with subcutaneous interferon beta-1a using RebiSmart® and assess injection-site reactions and treatment satisfaction. Methods: This prospective, single-arm, open-label, noninterventional multicenter Phase IV trial included disease modifying drug-experienced mobile patients with RRMS. Adherence was measured over 12 weeks. Items 13–23, 35, 37, and 38 of the Multiple Sclerosis Treatment Concerns Questionnaire (injection-site reactions and treatment satisfaction) were recorded at 12 weeks. Results: Sixty patients were recruited (mean age 43.7 [±SD 7.9] years; 83% female; mean years since multiple sclerosis diagnosis 6.7 [SD 4.5]). Adherence data were obtained in 54 patients only due to technical problems with six devices. Over 12 weeks, 89% (n=48) of patients had ≥ 90% adherence to treatment. Most patients experienced mild influenza-like symptoms and injection-site reactions, and global side effects were minimal. Most patients (78%) rated the convenience as the most important aspect of the device, and most experienced no or mild pain. Conclusion: RRMS patients treated with subcutaneous interferon beta-1a, administered with RebiSmart, demonstrated generally good adherence, and the treatment was generally well tolerated.

AB - Background: Disease modifying drugs help control the course of relapsing remitting multiple sclerosis (RRMS); however, good adherence is needed for long-term outcomes. Objective: To evaluate patient adherence to treatment with subcutaneous interferon beta-1a using RebiSmart® and assess injection-site reactions and treatment satisfaction. Methods: This prospective, single-arm, open-label, noninterventional multicenter Phase IV trial included disease modifying drug-experienced mobile patients with RRMS. Adherence was measured over 12 weeks. Items 13–23, 35, 37, and 38 of the Multiple Sclerosis Treatment Concerns Questionnaire (injection-site reactions and treatment satisfaction) were recorded at 12 weeks. Results: Sixty patients were recruited (mean age 43.7 [±SD 7.9] years; 83% female; mean years since multiple sclerosis diagnosis 6.7 [SD 4.5]). Adherence data were obtained in 54 patients only due to technical problems with six devices. Over 12 weeks, 89% (n=48) of patients had ≥ 90% adherence to treatment. Most patients experienced mild influenza-like symptoms and injection-site reactions, and global side effects were minimal. Most patients (78%) rated the convenience as the most important aspect of the device, and most experienced no or mild pain. Conclusion: RRMS patients treated with subcutaneous interferon beta-1a, administered with RebiSmart, demonstrated generally good adherence, and the treatment was generally well tolerated.

KW - Adherence

KW - Multiple sclerosis

KW - RebiSmart

KW - Relapsing remitting MS

KW - Subcutaneous interferon beta-1a

KW - Trial

U2 - 10.2147/PPA.S154417

DO - 10.2147/PPA.S154417

M3 - Journal article

C2 - 29720872

AN - SCOPUS:85045835635

VL - 12

SP - 569

EP - 575

JO - Patient Preference and Adherence

JF - Patient Preference and Adherence

SN - 1177-889X

ER -